anti-CD44 monoclonal antibodies (NEXTherapeutics)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD44 monoclonal antibodies (NEXTherapeutics)
Drug Alias NameCD44 inhibitor (NEXTherapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCD44 antigen inhibitors
TargetsCD44 antigen
Therapy Area/IndicationsArthritis, RheumatoidColorectal NeoplasmsBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNextherapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNextherapeutics
Active IndicationsN/A
Inactive IndicationsArthritis, RheumatoidColorectal NeoplasmsBreast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A